Skip to main content

Table 1 Genes mutated in our cohort and found to be significant

From: Mutational analysis of selected high-grade malignancies in a premenopausal gynecologic cancer population: a potential for targeted therapies?

Gene n = 20 p-value 1-tailed p-value 2-tailed Targeted Therapy
ASXL1 3 (15%) 0.120 0.022 Sorafenib (CMML with FLT3-ITD mutation and a corresponding ASXL1 mutation) 1
ALK 2 (10%) 0.010 0.022 Crizotinib (NSCLC with ALK-EML4 fusion transformation) 2 ; Ceritinib (NSCLC or other cancers) 3
EGFR 1 (5%) 0.065 0.130 Erlotinib (NSCLC) 4 ; Afatinib (NSCLC) 5 ; Gefitinib (NSCLC) 6
ERBB3 4 (20%) 0.014 0.028 MM-121 (Clinical Trial NSCLC; sensitizes to other chemo) 7 ; MM-111 (Clinical Trial Breast Cancer) 8 ; U3–1287/AMG-888 (Clinical Trial Metastatic BCA) 9
GPR124 4 (20%) 0.014 0.028 miR-138-5p (NSCLC cell lines; sensitizes to chemo) 10
KMT2D 4 (20%) 0.014 0.130 None currently; Aka MLL2; (Head and Neck cancer biology) 11
NTRK1 2 (10%) 0.109 0.022 Imatinib (Gleevec; GIST) 12
AKAP9 5 (25%) 0.050 0.100 None currently; (Breast, Thyroid) 13, 14
ASXL 2 (10%) 0.011 0.241 Sorafenib (CMML with FLT3-ITD mutation and a corresponding ASXL1 mutation) 1
CMPK1 5 (25%) 0.050 0.100 Deactivation of gemcitabine 15
MBD1 5 (25%) 0.050 0.100 Drug resistance (Pancreatic Cancer) 16
ROS1 5 (25%) 0.050 0.100 Crizotinib (NSCLC) 17
  1. Both 1-tailed and 2-tailed p-values were determined; significant 2-tailed p-values are considered more sensitive; bold items indicate the p-value for genes found to be significant between cohorts